Last updated on February 2009

Ciclophosphamide Vincristine Myocet and Prednisone With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

Brief description of study

The purpose of this study is to evaluate the efficacy (and safety) of the following treatment squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and Prednisone,combined with Rituximab in first line treatment for patients with aggresive No Hodgkin B lymphoma and cardiovascular risk

Detailed Study Description

Phase II, multicenter, open , 1-arm study.

Clinical Study Identifier: NCT00849355

Find a site near you

Start Over